Artivion (AORT) director receives 7,576-share equity grant, holds 46,960 shares
Anthony B. Semedo, a director at Artivion (AORT), received a grant of 7,576 shares of common stock as part of an equity award, with no cash payment per share. This award is scheduled to vest on May 18, 2027, under the company's Equity and Cash Incentive Plan. Following this transaction, Semedo directly holds 46,960 shares and indirectly owns an additional 600 shares through his spouse.
Artivion (AORT) director receives 7,576-share stock grant
Artivion (AORT) director Jeffrey H. Burbank was granted 7,576 shares of common stock at no purchase price on May 18, 2026, as part of the company's Equity and Cash Incentive Plan. These Restricted Stock Award (RSA) shares are scheduled to vest on May 18, 2027, and following this transaction, Burbank directly holds 61,372 shares of Artivion stock. This grant represents routine compensation rather than an open-market trade.
Artivion (AORT) director awarded 7,576 restricted common shares
Artivion (AORT) director Jon W. Salveson was awarded 7,576 restricted common shares as a stock grant, increasing his direct holdings to 137,416 shares. This award was granted at no cash cost and is scheduled to vest on May 18, 2027, under the company’s Equity and Cash Incentive Plan. The transaction was reported on a Form 4 filed with the SEC, indicating a compensation-related acquisition rather than an open-market purchase.
Artivion (AORT) director receives 7,576-share equity award grant
Artivion (AORT) director Thomas F. Ackerman was granted 7,576 restricted shares of common stock on May 18, 2026, at no cash cost. These shares will vest on May 18, 2027, as per the company's Equity and Cash Incentive Plan. Following this award, Ackerman's direct holdings in Artivion now total 157,472 shares.
Artivion Completes Endospan Acquisition, Expands Aortic Arch Portfolio With FDA-Approved NEXUS System
Artivion has finalized its acquisition of Endospan Ltd., integrating the FDA-approved NEXUS Aortic Arch System into its product lineup. This strategic move aims to bolster Artivion's presence in the endovascular aortic repair market and complement its existing portfolio with next-generation aortic arch technologies. The deal involves an upfront payment of approximately $131.3 million and potential milestone payments up to $200 million.
Artivion (AORT) director receives 7,850-share stock award, now holds 56,938
Artivion (AORT) Director Marna P. Borgstrom has received an equity compensation grant of 7,850 shares of Common Stock at a stated price of $0.00 per share, as reported in a Form 4 SEC filing. This award, part of the company's Equity and Cash Incentive Plan, increases her direct holdings to 56,938 shares. The RSA grant is scheduled to vest on May 14, 2027, aligning director compensation with the company's long-term performance.
Artivion closes Endospan buyout to acquire recently approved heart device
Artivion has finalized its acquisition of Endospan for an upfront payment of $131.3 million, securing the recently FDA-approved Nexus Aortic Arch System. The company plans to launch Nexus in the U.S. in January, targeting a $150 million annual market, and has identified around 100 high-volume accounts for initial sales. This acquisition strengthens Artivion's portfolio of treatments for aortic arch conditions.
Artivion secures FDA approval for NEXUS aortic arch system
Artivion, Inc. (AORT) announced that it has received FDA approval for its NEXUS Aortic Arch System, a significant milestone for the first and only de-branched stent graft designed for total aortic arch replacement. The company expects a limited market release of the new system in 2025, followed by a full market release in 2026. This approval positions Artivion to meet a major unmet clinical need and expand its market presence.
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition
Artivion has acquired Endospan in a $135 million upfront deal, exercising a license option following US FDA approval of Endospan's NEXUS aortic graft stent system. This acquisition, which includes potential additional payments up to $200 million based on commercial performance, significantly expands Artivion's aortic arch portfolio. The NEXUS system treats high-risk surgical patients with aortic arch disease, a condition affecting over 120,000 patients annually in the US and Europe.
Artivion Closes $175M Deal for Aortic Arch Maker Endospan
Artivion has finalized its acquisition of Endospan for $175 million, with potential additional payments up to $200 million based on performance. This acquisition follows the FDA approval of Endospan's Nexus aortic arch system, enhancing Artivion's global portfolio in aortic arch solutions. The move positions Artivion as a leader in the segment, offering a comprehensive suite of endovascular and hybrid solutions for aortic arch disease.
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Endospan has announced the closing of its acquisition by Artivion, Inc. for $175 million plus up to $200 million in performance-based consideration. This acquisition follows the April 2026 FDA PMA approval of Endospan's NEXUS® Aortic Arch System, an off-the-shelf endovascular solution for aortic arch disease. The integration of NEXUS into Artivion's portfolio aims to provide comprehensive solutions for aortic arch treatment, expanding global access to this technology.
Artivion Closes Endospan Acquisition Following FDA Approval of NEXUS Aortic System
Artivion Inc. has completed its acquisition of Israeli medical device company Endospan Ltd., following FDA approval of the NEXUS Aortic Arch System. This acquisition, valued at an upfront $175 million with potential additional payments, significantly expands Artivion's presence in the minimally invasive aortic repair market. The deal strengthens Artivion's strategy to provide comprehensive treatment options for complex aortic disease and leverages its existing international commercial infrastructure.
Artivion Completes Strategic Acquisition of Endospan Platform
Artivion announced the completion of its strategic acquisition of Endospan, a move that significantly expands its aortic arch portfolio. The deal, valued at a base of $175 million with potential for an additional $200 million, brings Endospan's FDA-approved NEXUS platform and pipeline of next-generation technologies under Artivion's ownership. This acquisition is expected to strengthen Artivion's position in the global aortic arch solutions market, despite an AI analyst's "Neutral" rating on AORT stock due to technical trends and valuation concerns.
Artivion completes acquisition of Endospan; $131.3M net upfront, up to $200M contingent
Artivion (AORT) has finalized the acquisition of Endospan for a net upfront payment of approximately $131.3 million, with potential additional contingent considerations of up to $200 million. The acquisition closed on May 18, 2026, following Artivion's exercise of its option to purchase Endospan securities, with the base purchase price being $175.0 million in cash. Artivion utilized a $150 million delayed draw term loan for the acquisition and has historically been the exclusive distributor for Endospan's NEXUS product in EMEA, which received FDA approval in April 2026.
Artivion completes $135 million Endospan acquisition
Artivion, Inc. has finalized its acquisition of Endospan Ltd. for $135 million, augmenting its position in the aortic device market with the NEXUS Aortic Arch System. This deal follows FDA approval for the NEXUS system and aims to complete Artivion's aortic arch portfolio, despite the company's stock facing a 50% year-to-date decline and appearing overvalued. Artivion recently reported mixed Q1 2026 financial results, beating EPS and revenue forecasts but missing some estimates and adjusting full-year guidance downward.
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
Endospan announced that Artivion, Inc. has closed its acquisition of the company after the FDA approved the NEXUS® Aortic Arch System. This strategic move, valued at $175M upfront plus potential additional consideration, integrates Endospan's innovative technology into Artivion's comprehensive portfolio, strengthening its leadership in aortic arch solutions. The acquisition solidifies Endospan's market position, especially in international markets where its technology is already established, and positions Artivion for a full U.S. commercial launch of the NEXUS system.
Endospan acquisition gives Artivion (NYSE: AORT) FDA-approved NEXUS aortic arch system
Artivion, Inc. (NYSE: AORT) has completed its acquisition of Endospan Ltd., gaining full ownership of the FDA-approved NEXUS Aortic Arch System and a pipeline of next-generation aortic arch technologies. The deal includes a $175 million base cash price and up to an additional $200 million in contingent consideration based on future NEXUS product performance. This strategic acquisition expands Artivion's aortic arch portfolio, positioning it as a key player in endovascular aortic disease treatment.
Aortic surgery firm Artivion buys Endospan, NEXUS arch stent maker
Artivion (NYSE:AORT) has completed its acquisition of Endospan Ltd., developer of the NEXUS Aortic Arch System, for an upfront net purchase price of $135 million, funded by a previously drawn $150 million term loan. This acquisition provides Artivion with full ownership of the NEXUS system, which received FDA PMA approval in April 2026, and a pipeline of next-generation arch technologies, thereby completing its three-part aortic arch portfolio alongside AMDS and ARCEVO LSA. The deal includes potential additional performance-based consideration for Endospan.
Artivion strengthens aortic arch portfolio with $135m Endospan acquisition
Artivion has acquired Endospan for an upfront payment of $135 million, with potential additional payments up to $200 million based on commercial performance. This acquisition follows a 2019 strategic deal made after Endospan's NEXUS aortic graft stent system received US FDA approval. The deal aims to strengthen Artivion's aortic arch portfolio with the addition of Nexus, designed to treat aortic arch disease, and expand its pipeline of next-generation arch technologies.
Artivion: $135 Million Endospan Acquisition Expands Aortic Arch Portfolio
Artivion has completed the acquisition of Endospan Ltd. for an upfront net purchase price of $135 million, funded by a $150 million delayed draw term loan. This acquisition, which includes potential additional consideration, follows the recent FDA approval of Endospan’s NEXUS Aortic Arch System and strengthens Artivion's aortic arch portfolio, positioning it as a leader in providing comprehensive solutions for aortic arch disease. Artivion's Chairman, President, and CEO, Pat Mackin, emphasized that this acquisition completes their three-pronged aortic arch portfolio and adds a robust pipeline of next-generation technologies.
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35% - News and Statistics
Artivion's Q1 2026 earnings saw revenue of $116.3 million, matching analyst estimates, but adjusted EPS missed expectations by 35.1% at $0.08 versus $0.12. The company attributed the shortfall to weak stent graft sales and delays in AMDS starter set sales due to hospital procurement issues, leading to a downward revision in full-year revenue and EBITDA guidance. Analysts questioned management on the conservatism of the revised guidance and the impact of future PMA approval for AMDS.
Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Artivion, Inc. (NYSE:AORT) has received a consensus "Moderate Buy" rating from analysts, with seven buy ratings and one hold rating, and an average 12-month target price of $47.83. The company outperformed Q4 earnings expectations, reporting EPS of $0.17 against a $0.14 consensus and revenue up 19.2% year-over-year. Despite positive analyst coverage, insider selling and trimmed price targets have seen the stock trading below recent averages, though institutional ownership remains high at 86.37%.
Artivion shareholders elect directors and approve executive compensation
Artivion, Inc. shareholders elected all nominated directors and approved the compensation for named executive officers at their 2026 Annual Meeting. The company's shares are down nearly 50% year-to-date, despite a market capitalization of $1.12 billion. Additionally, shareholders ratified Ernst & Young LLP as their independent accounting firm for the fiscal year ending December 31, 2026.
Artivion (AORT) shareholders approve directors, executive pay and Ernst & Young for 2026
Artivion, Inc. (AORT) shareholders approved all nine nominated directors, executive officer compensation in a non-binding advisory vote, and ratified Ernst & Young LLP as the independent public accounting firm for the year ending December 31, 2026. The decisions were made at the company's 2026 Annual Meeting of Stockholders on May 12, 2026, with all proposals receiving strong support. This report highlights key voting figures and details from the 8-K filing.
Artivion Shareholders Back Board, Pay and Auditor Choices
Artivion shareholders have re-elected all director nominees and approved executive compensation, as well as the independent auditor, Ernst & Young LLP, at their 2026 Annual Meeting. This decision signals strong investor confidence in the company's current leadership, strategic direction, governance, and financial oversight. Despite weak technicals and a demanding valuation, TipRanks’ AI Analyst, Spark, rates AORT as "Neutral," citing improving fundamentals and a constructive strategic narrative.
Artivion Inc (AORT) Shares Surge 3.1% -- What GF Score of 86 Tel
Artivion Inc (AORT) shares rose 3.1% to $22.93, despite significant volatility, and are considered undervalued by 18.8% based on the GF Value™ of $28.24. The company has a strong GF Score™ of 86/100, driven by excellent growth prospects (10/10), but insiders have shown a selling trend, offloading $5.0M worth of shares recently. Investors should weigh the undervaluation and growth potential against the insider selling activity.
5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call
Artivion (AORT) experienced a negative market reaction to its Q1 2026 earnings, missing adjusted profitability estimates and revising guidance due to lower stent graft sales and delays in AMDS starter set adoption. Analysts focused on the revised guidance's conservativeness, AMDS sales hurdles, and strategies for market expansion. Key catalysts for future performance include AMDS PMA approval and the integration of the Endospan acquisition.
Artivion, Inc. 2026 Q1 - Results - Earnings Call Presentation (NYSE:AORT) 2026-05-12
Artivion, Inc. (NYSE:AORT) released its Q1 2026 earnings, reporting an EPS of $0.08, which missed expectations by $0.04. However, the company's revenue reached $116.34 million, an increase of 17.54% year-over-year, beating estimates by $595.75K. The article highlights that the company published a slide deck in conjunction with its earnings call.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud Against Artivion, Inc.
Ademi LLP is investigating potential securities fraud claims against Artivion, Inc. This investigation follows allegations that Artivion may have issued materially misleading business information, which could lead to shareholder losses. Shareholders who have suffered losses are encouraged to contact Ademi LLP for further information.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.
Ademi LLP is investigating potential securities fraud claims against Artivion (NYSE: AORT) due to alleged inaccurate statements regarding its financial performance, business operations, and future prospects. This investigation follows Artivion's acknowledgment on May 7, 2026, of lower international stents sales attributed to supply chain issues. Shareholders who believe they have been affected are encouraged to contact Ademi LLP for more information.
Should Artivion’s Lowered 2026 Guidance and Endospan Deal Require Action From Artivion (AORT) Investors?
Artivion (AORT) reported increased first-quarter revenue but missed profit expectations and lowered its full-year 2026 guidance, primarily due to delayed U.S. commercial launch for its NEXUS system. The company also plans to acquire Endospan, funded by a significant loan, tying its future growth to complex aortic products and the successful commercialization of NEXUS in 2027. This shift in guidance and the debt-funded acquisition could intensify both the potential upsides and downsides for investors, necessitating a reassessment of its investment narrative.
Artivion, Inc. (NYSE:AORT) Q1 2026 Earnings Call Transcript
Artivion, Inc. (NYSE:AORT) reported Q1 2026 earnings, exceeding EPS expectations with $0.08 against an anticipated $0.06. The company announced the acquisition of Endospan and its NEXUS aortic arch stent graft system, completing its comprehensive aortic arch portfolio. Despite revenue growth of 12% and adjusted EBITDA growth of 26%, the company adjusted its full-year 2026 revenue guidance to 7-11% constant currency growth due to slower-than-expected AMDS starter set sales and international market softness, primarily in the Middle East.
Artivion Q1 Earnings Call Highlights
Artivion reported double-digit revenue and adjusted EBITDA growth in Q1 2026, driven by its product portfolio, but lowered its full-year revenue outlook due to softer stent graft trends. The company is moving forward with the acquisition of Endospan, whose NEXUS Aortic Arch Stent Graft system recently received FDA approval, and expects it to contribute to long-term growth. Despite some challenges with initial U.S. AMDS account stocking and international stent graft sales, Artivion highlighted strong reorder activity for AMDS and growth in its On-X and tissue processing segments.
ARTIVION, INC. 1Q 2026: Revenue $116.34M, EPS $0.03— 10-Q Summary
ARTIVION, INC. reported strong first-quarter 2026 results, achieving profitability with diluted EPS of $0.03 and significant revenue growth to $116.34M, marking a 17.5% increase year-over-year. The growth was primarily driven by aortic stent grafts, On-X, preservation services, and sealants, with notable performance in North America and EMEA. The company also increased operational investments and R&D spending to support manufacturing, commercialization, and regulatory approvals.
Artivion Stock Dips 28% In One Day, Now Is Not The Time To Buy The Stock
The article reports that Artivion stock experienced a significant 28% drop in a single day, leading to the conclusion that it is currently not a good time to invest in the stock. The content itself seems to be a placeholder or incomplete article from Trefis, focusing more on site navigation and disclaimers.
Artivion (AORT) Earnings Turn Positive Challenging Cautious Profitability Narratives
Artivion (AORT) has reported turning a profit in FY 2025, with Q4 revenue of US$116.0 million and basic EPS of US$0.05, signaling a shift from previous losses. The company's trailing twelve-month figures show US$441.3 million in revenue and a net income of US$9.8 million. While full-year earnings are positive, quarterly EPS showed some fluctuation, and the stock trades at a P/S of 3.9x, with a DCF fair value and analyst target above its current share price.
Artivion Down Over 25%, On Pace for Largest Percent Decrease Since September 2022 -- Data Talk
Artivion (AORT) stock is experiencing a significant downturn, dropping over 25% and poised for its largest percentage decrease since September 2022. This performance deviates sharply from its 52-week average, leading to speculative interest regarding potential rebound opportunities or further declines. This article provides a snapshot of the current stock performance and analysts' price targets.
Artivion (NYSE: AORT) Q1 revenue rises 18% to $116M with profit
Artivion (NYSE: AORT) reported robust Q1 2026 financial results, with revenue increasing 18% year-over-year to $116.3 million and achieving a net profit of $1.4 million, reversing a prior-year loss. This growth was fueled by strong sales across aortic stent grafts, On-X heart valves, surgical sealants, and preservation services, complemented by favorable foreign exchange rates. The company also announced its exercise of the option to acquire Endospan for $135.0 million, to be funded by a new delayed draw term loan facility.
Artivion Inc stock hits 52-week low at $27.31
Artivion Inc (AORT) stock recently hit a 52-week low of $27.31, further declining to $24.10, despite having a 1-year return of approximately 24%. The medical device company maintains a market capitalization of $1.72 billion with analysts expecting net income growth this year. The drop follows first-quarter 2026 earnings where, despite beating EPS forecasts, the company reduced its full-year revenue and adjusted EBITDA guidance, leading analysts to lower price targets.
Artivion: Q1 Earnings Snapshot
Artivion (AORT) reported a first-quarter net income of $1.4 million, or 3 cents per share, a significant improvement from a loss in the same period last year. Adjusted earnings were 8 cents per share, with revenue reaching $116.3 million. The biological medical device maker anticipates full-year revenue between $480 million and $496 million.
Artivion Acquires Endospan to Expand Aortic Arch Portfolio
Artivion (AORT) announced strong first-quarter 2026 results with significant revenue and adjusted EBITDA growth, largely driven by stent grafts, On-X valves, preservation services, and BioGlue. Following FDA approval for Endospan’s NEXUS Aortic Arch System, Artivion exercised its option to acquire Endospan for approximately $135 million upfront plus potential performance-based earnouts. While the company adjusted its 2026 outlook due to transitional factors and a planned 2027 U.S. launch for NEXUS, this acquisition is expected to greatly enhance Artivion's aortic arch portfolio and future growth.
Artivion: Q1 Earnings Snapshot
Artivion, Inc. (AORT) reported a net income of $1.4 million in the first quarter, a significant improvement from a loss in the same period last year. The company achieved earnings of 3 cents per share, or 8 cents per share when adjusted, on revenues of $116.3 million. Artivion anticipates full-year revenue to be between $480 million and $496 million.
Artivion (NYSE: AORT) grows Q1 sales, eyes Endospan acquisition
Artivion (NYSE: AORT) reported strong Q1 2026 financial results with an 18% GAAP revenue increase to $116.3 million and a 26% rise in adjusted EBITDA. The company also announced its decision to acquire Endospan following FDA approval of the NEXUS Aortic Arch System, aiming to expand its aortic arch portfolio. Despite the positive Q1, Artivion lowered its full-year 2026 revenue and adjusted EBITDA guidance due to anticipated lower growth and integration costs for the Endospan acquisition.
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
Artivion, Inc. announced its financial results for the first quarter of 2026, reporting an 18% GAAP revenue increase to $116.3 million and a 26% rise in adjusted EBITDA to $22.1 million. The company also confirmed the exercise of its option to acquire Endospan for $135 million, following U.S. FDA PMA approval for the NEXUS Aortic Arch System. Although first-quarter performance fell slightly short of constant currency expectations, Artivion adjusted its full-year 2026 revenue guidance to $480-$496 million and adjusted EBITDA to $100-$107 million, citing continued strategic execution and product pipeline advancements.
Artivion earnings on deck: NEXUS approval raises growth stakes
Artivion Inc. will report first-quarter earnings, with analysts expecting 4.2 cents per share and $115.77 million in revenue. The recent FDA approval of the NEXUS Aortic Arch System and the looming decision on acquiring Endospan for $135 million are key factors influencing investor sentiment and future growth. Investors will focus on comments regarding the Endospan acquisition, early performance of new product launches (AMDS and NEXUS), and the sustainability of revenue growth and profitability.
Artivion Q1 2026 Earnings Preview — May 7, Street Expects $0.12 EPS
Artivion (AORT) is set to report its Q1 2026 earnings on May 7, with Wall Street analysts expecting a modest profit of $0.12 EPS on $115.7 million in revenue. This forecast indicates a significant turnaround from Q1 2025's loss and revenue growth of 16.9% year-over-year. Investors will be watching for sustained profitability, margin expansion, and commentary on the company's growth strategies in the competitive medical device market.
Earnings Preview: Artivion to Report Financial Results Post-market on May 07
Artivion (AORT) is expected to report its financial results post-market on May 07, with analysts forecasting a loss of $0.03 per share for the fiscal quarter. The company will also hold a conference call to discuss its Q1 2024 results, providing insights into its future performance. In 2023, Artivion reported a GAAP loss of $0.09 per share for the first quarter, highlighting investor focus on improved profitability and revenue growth.
Freedom Capital Markets initiates Artivion stock with buy rating
Freedom Capital Markets has initiated coverage on Artivion Inc. (NYSE:AORT) with a buy rating and a price target of $45.00, suggesting a 26% upside. The firm's bullish outlook is based on anticipated U.S. launches, strong gross profit margins, and expected EBITDA margin expansion. This follows recent regulatory approval for Artivion's NEXUS system and reiterated Buy ratings from Needham and Stifel.
Freedom Capital Markets initiates Artivion stock with buy rating By Investing.com
Freedom Capital Markets initiated coverage on Artivion Inc. (NYSE:AORT) with a "buy" rating and a $45.00 price target, citing expected growth from U.S. launches of AMDS and NEXUS, continued momentum in On-X U.S. sales, and EBITDA margin expansion through product mix shifts and operating expense leverage. This positive outlook follows FDA approval for Artivion's NEXUS Aortic Arch System and strong fourth-quarter adjusted revenues.
Artivion (AORT) to Release Quarterly Earnings on Thursday
Artivion (NYSE: AORT) is scheduled to release its Q1 2026 earnings after market close on Thursday, May 7th. Analysts anticipate earnings of $0.06 per share and revenue of approximately $115.78 million. In the previous quarter, Artivion surpassed estimates with an EPS of $0.17 and revenue of $118.3 million, marking a 19.2% year-over-year increase, while analyst sentiment remains a "Moderate Buy" with a $51.00 price target.
